Neodopaston combination tablets L250 (YJ code: 1169101F2045, standard: 1 tablet) are manufactured by Ohara Pharmaceutical. This medication combines levodopa, which is converted to dopamine in the brain, with carbidopa, preventing its peripheral breakdown, to treat Parkinson’s disease and parkinsonian syndrome.
Neodopaston combination tablets L250
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →More with the same ingredient
